Seven Eight Capital’s Integra LifeSciences IART Stock Holding History

Seven Eight Capital’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-40,413	Closed	-$734K	–	286
2024 Q3	$734K	Buy	+40,413	New	+$937K	0.07%	480
2024 Q2	–	Sell	-41,665	Closed	-$1.48M	–	798
2024 Q1	$1.48M	Buy	41,665 +4,584	+12%	+$183K	0.15%	208
2023 Q4	$1.61M	Buy	+37,081	New	+$1.46M	0.19%	159
2023 Q3	–	Sell	-17,017	Closed	-$700K	–	647
2023 Q2	$700K	Buy	+17,017	New	+$819K	0.12%	242
2022 Q3	–	Sell	-8,025	Closed	-$434K	–	548
2022 Q2	$434K	Buy	+8,025	New	+$482K	0.17%	193
2020 Q4	–	Sell	-11,100	Closed	-$524K	–	511
2020 Q3	$524K	Buy	+11,100	New	+$528K	0.11%	331
2020 Q1	–	Sell	-5,273	Closed	-$307K	–	570
2019 Q4	$307K	Sell	5,273 -27,200	-84%	-$1.62M	0.02%	580
2019 Q3	$1.95M	Buy	32,473 +28,600	+738%	+$1.7M	0.1%	293
2019 Q2	$216K	Sell	3,873 -13,900	-78%	-$716K	0.01%	551
2019 Q1	$990K	Buy	+17,773	New	+$905K	0.05%	360
2017 Q2	–	Sell	-3,700	Closed	-$156K	–	615
2017 Q1	$156K	Buy	+3,700	New	+$158K	0.03%	380

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Seven Eight Capital's IART Position: Q4 2024 in Review

Seven Eight Capital sold out of Integra LifeSciences (IART) in Q4 2024, closing a stake of 40,413 shares — an estimated $734K sold.

Seven Eight Capital first reported a position in IART in Q1 2017 and held it in 11 quarters. The position peaked at $1.95M in Q3 2019. 223 funds tracked by Wall St. Rank hold IART as of Q4 2024.

Seven Eight Capital reported no remaining Integra LifeSciences position as of Q4 2024 after selling out during the quarter.
Seven Eight Capital sold 40,413 Integra LifeSciences shares in Q4 2024, an estimated $734K.
Seven Eight Capital first reported a position in Integra LifeSciences in Q1 2017 and held it in 11 quarters.
Seven Eight Capital's Integra LifeSciences position peaked at $1.95M in Q3 2019.
223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.